Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lipiodol as an Imaging Biomarker of Tumor Necrosis After Transcatheter Chemoembolization Therapy in Patients With Primary and Metastatic Liver Cancer

NCT01877187 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT01877187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01877187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lipiodol as an Imaging Biomarker of Tumor Necrosis After Transcatheter Chemoembolization Therapy in Patients With Primary and Metastatic Liver Cancer
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2013
Completion date
February 29, 2020
Enrollment
39 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer